The Immune Tolerance Network (ITN), led by Benaroya Research Institute (BRI), has made major breakthroughs in fighting peanut allergies.
Carla Greenbaum, MD, has been named chair of Type 1 Diabetes TrialNet.
Over the last few years, several unique and pioneering technologies at BRI have been combined to create a “pipeline” approach to find and study rare disease-associated cells.
A simple blood test for family members of those living with type 1 diabetes may detect autoantibodies that show an increased risk years before symptoms appear.
The Immune Tolerance Network’s (ITN) TrialShare Clinical Trials Research Portal has won the National Academy of Scie
© 2020 Benaroya Research Institute at Virginia Mason. 1201 Ninth Avenue, Seattle, WA 98101-2795